KeyBanc lowered the firm’s price target on Avid Bioservices to $14 from $20 and keeps an Overweight rating on the shares. With capacity expansion over, maintenance capex of low single digit millions has moved Avid Bioservices past its intensive cash burn stage, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CDMO:
- Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023
- CDMO Earnings this Week: How Will it Perform?
- Alkermes, Armstrong World, National Healthcare, PJT Partners to join S&P 600
- Avid Bioservices partners with CIRM to provide CDMO services for CGT programs
- Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs